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Abstract
Background: Dyspnea is a common symptom experienced by many patients with chronic, life-threatening, and/
or life-limiting illnesses. Although it can be defined and measured in several ways, dyspnea is best described
directly by patients through regular assessment, as its burdens exert a strong influence on the patient’s expe-
rience throughout the trajectory of serious illness. Its significance is amplified due to its impact on family and
caregivers.
Discussion: Anatomic and physiologic changes associated with dyspnea, and cognitive perceptions related to
patients and the underlying disease, provide insights into how to shape interventions targeting this oppressive
symptom. Additionally, as described in the concept of ‘‘total dyspnea,’’ the complex etiology and manifestation
of this symptom require multidisciplinary treatment plans that focus on psychological, social, and spiritual
distress as well as physical components. Several validated assessment tools are available for clinical and research
use, and choice of method should be tailored to the individual patient, disease, and care setting in the context of
patient-centered care.
Conclusion: This article, the first in a two-part series, reviews the identification and assessment of dyspnea, the
burden it entails, and the underlying respiratory and nonrespiratory etiologies that may cause or exacerbate it.
Introduction
The word ‘‘dyspnea’’ is derived from the Greek roots dys,meaning difficult, and pneuma meaning breath. Dyspnea,
or breathlessness, is a common and oppressive symptom ex-
perienced by many patients throughout the trajectory of life-
limiting illness. Dyspnea may be related to the illness, its co-
morbidities, therapy for either, or hypoxia. Often it is the re-
sult of a combination of all these. Dyspnea may occur at rest or
with activity, may be continuous, intermittent or have a pat-
tern of acute-on-chronic experiences and effects those with
and without primary cardiopulmonary disorders alike. As
breathing is a primal sensation of life, its disturbance creates a
visceral sense of dread that, itself, incurs suffering. Dyspnea is
a reason for consultation in over 10% of palliative care inpa-
tient consultations1 and is the fourth most common reason for
palliative care patients to visit the emergency department.2 In
this first of a two-part series on dyspnea for the palliative care
professional, we review the burden, pathophysiology, and
measurement of dyspnea. The next review will appraise both
pharmacologic and nonpharmacologic options for dyspnea
management.
Definitions
The American Thoracic Society defines dyspnea as ‘‘a
subjective experience of breathing discomfort that consists of
qualitatively distinct sensations that vary.’’3 In more collo-
quial terms, dyspnea is an uncomfortable breathing sensation
that is subjective and difficult to define by the outsider; pa-
tients ‘‘know it when they feel it.’’ Table 1 lists examples in-
cluded in dyspnea assessment questionnaires to describe the
symptom. Descriptors used by patients to express degrees of
dyspnea or breathlessness fall into the general categories of
difficulty with air movement (‘‘I feel that my breathing is more
rapid.’’ ‘‘My breath does not go out all the way.’’), increased
effort (‘‘I feel that I am breathing more.’’ ‘‘I feel hunger for
more air.’’), and general distress (‘‘I feel I am suffocating.’’
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‘‘I feel that I am smothering.’’).4 This symptom may be con-
stant (i.e., continuous dyspnea) or present in episodes (i.e.,
breakthrough dyspnea) as described in a cohort of cancer
patients by Reddy et al.5 Breakthrough dyspnea was the
predominant type, with over 80% of patients reporting short
spells of breathlessness interrupting long symptom-free pe-
riods throughout the day. Continuous dyspnea was reported
by only 39% of patients. On average, breakthrough episodes
occurred 5–6 times per day and lasted less than 5 minutes,
indicating that tailored treatment paradigms with quick onset
of action are needed to counteract this more common type.
Although dyspnea has traditionally been described in the
medical literature by physiologic measures, there is a growing
acknowledgment that it is ultimately a patient-centered
symptom that does not necessarily correlate with findings of
hypoxia, hypercarbia, or tachypnea. Correspondingly, pa-
tient-reported experience of the symptom has become the
standard for assessment, and an increasingly accepted
method for determining its severity and impact. Because of its
many correlates with the patient’s underlying disease, de-
mographic background, concomitant symptoms, and emo-
tional state, each patient’s experience of dyspnea becomes as
unique to the individual as is their journey with life-limiting
illness.
Burden and Consequences in Advanced Disease
Dyspnea is either an element of the disease course or a
component of the final stages of most etiologies that cause
significant morbidity and mortality in the United States.
Dyspnea is experienced at some point by most patients with
advanced cancer,6 heart failure,7 and chronic lung disease8
and in the last 3 days of life in the imminently dying.9 In fact,
Currow et al.10 recently reported that only 11.4% of patients
receiving end-of-life care report ‘‘no breathlessness.’’ Given
that cancer, heart failure, and chronic lung disease represent,
respectively, the first, second, and fourth most common cau-
ses of death in the United States and account for over 50% of
all deaths,11 dyspnea therefore afflicts a large population of
patients. Dyspnea is also a significant part of the symptom
milieu of patients with dementia,12 advanced age,13 and
HIV.14 Correspondingly, dyspnea remains a major target for
intervention in palliative care. Among patients receiving end-
of-life care, shortness of breath was the seventh most observed
symptom, affected almost 50% of all patients, was reported as
‘‘severe’’ in half of those experiencing it,15 and increased sig-
nificantly between 3 months and 1 month before death.9,16
The presence of dyspnea in patients with life-altering dis-
ease can exert a profound effect on patient and caregiver
quality of life. Often patients notice and caregivers observe a
gradual loss of independence, progressing from initial diffi-
culty with pleasurable activities to ultimate loss of ability to
perform even the most routine activities of daily living. Pa-
tient reports of increasing levels of dyspnea have correlated
with lower quality-of-life scores overall17 and with physical,
emotional, and cognitive changes including anorexia, fatigue,
poor concentration, memory loss, and decreased mastery.18
A recent review of over 1600 patients with severe ob-
structive lung disease from the National Emphysema Treat-
ment Trial showed that dyspnea was strongly and inversely
associated with health-related quality of life (HRQOL) inde-
pendent of forced expiratory volume in 1 second (FEV1)
measure.19 Interventions associated with increased HRQOL
included pulmonary rehabilitation and supplemental oxygen.
Another recent study conducted in a population of patients
with chronic obstructive pulmonary disease (COPD), 94% of
whom reported dyspnea, found a positive association be-
tween increasing symptom burden and decreased quality of
life.20 In a multivariate analysis, Reddy et al.5 recently re-
ported an association between dyspnea and depression, and
documented the effect of increasing dyspnea intensity on in-
terference with general activity, mood, and enjoyment of life.
The impact of uncontrolled dyspnea extends beyond the pa-
tient to affect family members and other caregivers, health
care staff, and the health care delivery system. In the setting of
worsening dyspnea, patients and families are often faced with
difficult decisions regarding care advancement (e.g., me-
chanical ventilation versus noninvasive positive pressure
ventilation versus other symptom treatment) or change in
locations of care (e.g., hospital versus home). Dyspnea is a risk
factor for hospitalization in patients with lung cancer21 and
for in-hospital death, independent of underlying illness, for
anyone with advanced disease who is enrolled in home-based
health care.22 Significant associations have been reported be-
tween dyspnea and decreased patient and family well-being
and increased staff anxiety, highlighting the impressive effect
of this one symptom on the patient, his/her support network,
and the health care delivery system.
Not surprisingly, dyspnea is frequently included as a
component of prognostic models of death from pulmonary
and nonpulmonary disease. Two decades ago, Carpenter
et al.23 reported that symptoms of breathlessness are a pre-
dictor of death from all causes over a period of 27 years—even
when the symptom was episodic. The Bode Scale, a tool used
to determine prognosis of COPD patients over 1 to 3 years,
has as its only patient-experienced component the measure-
ment of dyspnea on a scale from 0–4.24 The Mortality Risk
Index Score incorporates dyspnea as an important part of the
6-month assessment of prognosis in elderly, nursing home
residents.25 The Palliative Prognostic Score, a tool to stratify
patients into groups based on predicted 30-day survival, also
uses the presence of dyspnea as an integral part of its survival
prediction.26
Etiologies of Dyspnea
Patterned after the concept of total pain first described by
Dame Cicely Saunders in the 1960s, the concept of ‘‘total
dyspnea’’ creates a framework for understanding dyspnea
etiology in a way that captures its full impact on the patient
and caregiver.27 Encompassing the four domains of physical,
psychological, interpersonal, and existential distress, total
Table 1. Patient Descriptors of Dyspnea





Take a full breath
That my breath
stops
Chest feels tight Get enough air
That I am
suffocating
Breathing is fast Stop thinking about
my breathing
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dyspnea describes the patient’s experience of the symptom
from multiple perspectives that, synergistically, combine to
shape the symptom and to determine its impact (Fig. 1). A
mnemonic encompassing these various biopsychosocial
components is presented in Figure 2. This approach is wholly
consistent with the multidisciplinary nature central to pallia-
tive care.
Physiologically, dyspnea results from three main abnor-
malities: increased load requiring greater respiratory effort
(e.g., obstruction), an increase in the proportion of respiratory
muscle required to maintain a normal workload (e.g., weak-
ness), and an increase in ventilator requirements (e.g. fever,
anemia). The anatomic condition and underlying disease
giving rise to dyspnea may be pulmonary obstruction (COPD,
reactive airways, cough/secretions, mass lesions), pulmonary
restriction (fibrosis or other interstitial disease, effusions, fi-
brosis, infections, kyphosis, obesity), perfusion/oxygenation
mismatch (anemia, pulmonary hypertension, heart failure,
pulmonary embolism), and fatigue/weakness (multiple scle-
rosis, amyotrophic lateral sclerosis, cancer fatigue). Although
abnormalities can often be measured, imaged, or assumed
based on underlying disease, etiologies of dyspnea are often
related to systemic effects of illness. For example, data from
the National Hospice Study reported that 24% of patients with
no known cardiopulmonary process (e.g., local cancer in-
volvement, pleural effusions, pulmonary infections) experi-
ence dyspnea.6 Additionally, in hospice patients with no
known cardiopulmonary disorder, both prevalence and se-
verity of dyspnea increase significantly as death ap-
proaches.10 In such cases, systemic changes such as asthenia
and cachexia, both of which are present in greater than 80% of
people with advanced cancer, are postulated as etiologies.28
Other nonanatomic correlates of dyspnea include affect and
spiritual and existential distress. Patient anxiety and panic
both play an important role in the development of dyspnea
and, in turn, are exacerbated by its presence—setting up a
pernicious spiral of cause and symptom (Fig. 3). The associ-
ation between symptoms of breathlessness and anxiety, par-
ticularly panic attacks, is well-documented. This association
bears notice given the high prevalence of anxiety in palliative
care populations. One recent study reported that 22% of pa-
tients in an inpatient palliative care unit met Hospital Anxiety
and Depression Scale (HADS) criteria for anxiety.29 It has also
been observed that, compared to control patients, patients
with underlying anxiety or panic disorders have an exag-
gerated experience of dyspnea.30 Additionally the effect of
spiritual distress on dyspnea has been recently described.22
The central nervous system (CNS) also plays a critical role
in the perception of dyspnea. In the accepted neurophysio-
logic model, it is thought that dyspnea arises when sensory
receptors involved with respiration are activated, sending an
afferent impulse to the CNS; the CNS then directs an efferent
impulse toward the muscles of respiration. Mismatch be-
tween these signals may contribute to dyspnea through
modulation of any of these systems.31 It has been postulated
since 1985 that endogenous opioids, known as endorphins,
may attenuate the dyspnea sensation at the CNS level.32 An
important recent investigation antagonizing endogenous en-
dorphins in opioid-naı̈ve volunteers has added to the un-
derstanding of the efficacy of exogenous opioids as the
mainstay of global therapy for dyspnea. Mahler et al.33 con-
ducted an investigation measuring beta-endorphin levels at
rest and post-exercise in 17 patients with COPD undergoing a
10-minute treadmill exercise test. Patients were given either
intravenous saline or naloxone, measured for beta-endorphin
serum levels, and queried for numerical rating score of dys-
pnea. A threefold increase in serum beta-endorphin levels
was observed from rest to postexercise. Mean ratings of
dyspnea throughout exercise were significantly higher in
patients when they received naloxone.33 This recent proof of
concept suggests that further studies are warranted to identify
ways in which the endogenous opioid effect on dyspnea can
be accentuated.
Additionally, increasing investigations with positron
emission tomography (PET)34–36 and functional magnetic
resonance imaging (fMRI) have added to the knowledge of
how dyspnea activates cortical and cerebellar systems.37
Measurement of Dyspnea
Various validated measurement tools are available to as-
sist the palliative care professional in quantitatively and
FIG. 1. Elements of the biopsychosocial model of ‘‘total
dyspnea.’’
FIG. 2. Mnemonic of the biopsychosocial elements of
dyspnea.
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qualitatively assessing the patient’s dyspnea. These instru-
ments range from standard single-item ordinal scales such as
the visual analogue scale (VAS), numerical rating scale (NRS,
e.g., 0 [no breathlessness] to 10 [worst possible breathless-
ness]), and modified Borg scale38 to measure the intensity of
breathlessness to functional assessment scales such as the
Medical Research Council Dyspnea Scale and Baseline Dys-
pnea Index (BDI). Research studies typically employ more
complex measurements of physiologic parameters such as the
6-minute walk test, alone or in combination with surveys
describing the patient’s symptom experience39 (e.g., ‘‘I feel out
of breath’’, ‘‘My chest feels tight’’). Certain categorical tools
such as the Memorial Symptom Assessment Scale and Ed-
monton Symptom Assessment Scale (ESAS) incorporate
numerical ratings of dyspnea into an overall symptom in-
ventory. Dorman et al.40 recently presented a comprehensive,
systematic review of measurement scales for dyspnea in
palliative care that includes many other scales not covered
here.
Recent attention has been drawn to the need for a practical
assessment tool that describes the patient’s experience of
dyspnea and is useful in the clinical setting as well as for
research purposes. While several validated scales are used in
the research setting to measure the impact of dyspnea on
HRQOL, most of these are too long and arduous to be prac-
tical in routine clinical care. To better reflect the patient’s ex-
perience rather than focusing on physiologic parameters,
Tanaka et al.41 developed the Cancer Dyspnea Scale, a 12-item
multidimensional dyspnea scale for patients with cancer to
assess effort, anxiety, and discomfort. Originally validated in
a Japanese population, it has subsequently been validated in
Swedish-speaking42 and English-speaking43 cohorts. This ef-
fort represents a step forward in incorporating the patient’s
symptom experience into dyspnea assessment, but falls short
of assessing the full impact of dyspnea. To date, no single
assessment tool considers all of the various components of
this multifaceted symptom and its impact on people.
Ultimately, when selecting assessment measures in pallia-
tive care, the clinician must take into account the goals of care,
purpose of the assessment, ease of administration, and patient
burden, with the aim of gathering useful information while
not detracting from quality of life by being tedious, distres-
sing, intensive, or complicated. In clinical practice, the most
fruitful way of measuring experience is simply to ask, inter-
vene, follow up, and ask again – using the same scale each
time (Figure 3). Clinically, a straightforward standardized
scale (e.g., 0–10 NRS) alone or as a part of a longer symptom
list (e.g., ESAS) is likely best. More complex tools (e.g., Cancer
Dyspnea Scale) have not yet demonstrated their role in clinical
practice, but in the research setting they can help identify
etiologies and document change in complex outcomes in re-
sponse to therapies. Additionally, the evolving understand-
ing that most dyspnea is intermittent, as opposed to
continuous, means that a thorough assessment involves
questioning both the patient’s current symptom burden and
experiences over the last 24 hours.
Conclusion
Dyspnea, a complex and commonly experienced symptom,
worsens in prevalence and intensity for many palliative care
patients. Its dramatic effects on independence and quality of
life make prompt recognition and characterization of under-
lying causes and comorbidities paramount. Various tools to
measure dyspnea are available to the clinician and researcher,
but often the most useful and well-received are those that are
short, to the point, and used regularly to monitor symptom
status. Most importantly, the actual words of the patient re-
flect the true meaning of dyspnea, its burden, and the impact
of therapeutic interventions. The field of palliative care is
expanding and the patient population evolving. An increas-
ing proportion of inpatient palliative care consultations are
being performed on patients without cancer, such as indi-
viduals receiving advanced therapies for COPD and heart
failure. As the population of those with life-limiting illnesses
referred to palliative care grows, further research and clinician
education are critical; we must continue to refine and improve
our understanding of, ability to recognize, and capacity to
effectively treat this disabling symptom.
In a subsequent article, we will explore pharmacologic and
nonpharmacologic interventions for dyspnea.
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